Vancomycin Related Published Studies
Well-designed clinical trials related to Vancomycin
Reduced acquisition and overgrowth of vancomycin-resistant enterococci and
Candida species in patients treated with fidaxomicin versus vancomycin for
Clostridium difficile infection. [2012]
Meta-analysis of randomized controlled trials of vancomycin for the treatment of
patients with gram-positive infections: focus on the study design. [2012]
Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan. [2011.04]
Fidaxomicin versus vancomycin for Clostridium difficile infection. [2011.02.03]
Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. [2011.01.01]
Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam
in the treatment of complicated skin and skin structure infections in patients
from India and Taiwan. [2011]
Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive
pathogens. [2011]
ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections. [2010.12]
Retrospective cohort study of hospitalized adults treated with vancomycin or clindamycin for methicillin-resistant Staphylococcus aureus skin infections. [2010.11]
Co-trimoxazole versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia: a retrospective cohort study. [2010.08]
Probiotics and intestinal colonization by vancomycin-resistant enterococci in mice and humans. [2010.07]
Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. [2010.06]
Comparison of continuous infusion versus intermittent infusion of vancomycin in patients with methicillin-resistant Staphylococcus aureus. [2010.02]
Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. [2010.01]
[Linezolid versus vancomycin in the treatment of pneumonia caused by
Gram-positive cocci: meta-analysis of randomised controlled trials]. [Article in Chinese] [2010]
Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized,
double-blind studies to evaluate the safety and efficacy of ceftaroline versus
vancomycin plus aztreonam in complicated skin and skin-structure infection. [2010]
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures. [2009.06]
The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. [2009.03]
Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. [2009.02.15]
Nitazoxanide versus Vancomycin in Clostridium difficile Infection: A Randomized, Double-Blind Study. [2009.01.09]
Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. [2008.12]
Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. [2008.12]
Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. [2008.09]
Vancomycin for the treatment of Clostridium difficile Infection: for whom is this expensive bullet really magic? [2008.05.15]
Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. [2008.04]
A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. [2008.03.01]
Efficacy and safety study of fixed-dose combination of ceftriaxone-vancomycin injection in patients with various infections. [2008.01]
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. [2007.08.01]
Bowel colonization with vancomycin-resistant enterococci after antimicrobial therapy for intra-abdominal infections: observations from 2 randomized comparative clinical trials of ertapenem therapy. [2007.08]
Successful prevention of tunneled, central catheter infection by antibiotic lock therapy using vancomycin and gentamycin. [2007.06]
Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. [2007.05.07]
Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. [2007.01.15]
What to think if the results of the National Institutes of Health randomized trial of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus control measures are negative (and other advice to young epidemiologists): a review and an au revoir. [2006.10]
Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. [2006.08.15]
Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. [2006.08]
Prospective randomized controlled trial of the effect of intracameral vancomycin and gentamicin on macular retinal thickness and visual function following cataract surgery. [2006.05]
Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. [2006.03.01]
Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). [2005.12]
Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. [2005.11]
Effect of intravitreal dexamethasone on vitreous vancomycin concentrations in patients with suspected postoperative bacterial endophthalmitis. [2005.11]
Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. [2005.09]
A vancomycin-heparin lock solution for prevention of nosocomial bloodstream infection in critically ill neonates with peripherally inserted central venous catheters: a prospective, randomized trial. [2005.08]
Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. [2005.06]
Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. [2005.04]
Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. [2005.02]
Well-designed clinical trials possibly related to Vancomycin
Fidaxomicin preserves the intestinal microbiome during and after treatment of
Clostridium difficile infection (CDI) and reduces both toxin reexpression and
recurrence of CDI. [2012]
Fidaxomicin attains high fecal concentrations with minimal plasma concentrations
following oral administration in patients with Clostridium difficile infection. [2012]
Decreased cure and increased recurrence rates for Clostridium difficile infection
caused by the epidemic C. difficile BI strain. [2012]
Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a
randomized, controlled study. [2012]
New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis,
treatment and resistance. [2012]
Adjunctive use of intravitreal dexamethasone in presumed bacterial endophthalmitis: a randomised trial. [2011.10]
Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. [2011.09.07]
Tigecycline for the treatment of severe Clostridium difficile infection. [2011.07]
Intervention to reduce transmission of resistant bacteria in intensive care. [2011.04.14]
The impact of enhanced cleaning within the intensive care unit on contamination of the near-patient environment with hospital pathogens: a randomized crossover study in critical care units in two hospitals. [2011.04]
Adjunctive use of intravitreal dexamethasone in presumed bacterial
endophthalmitis: a randomised trial. [2011]
Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. [2010.11]
CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. [2010.11]
CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. [2010.11]
Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial. [2010.11]
Vascular surgical antibiotic prophylaxis study (VSAPS). [2010.10]
Antibiotic prophylaxis in primary hip and knee arthroplasty comparison between cefuroxime and two specific antistaphylococcal agents. [2010.10]
Daptomycin compared to standard therapy for the treatment of native valve endocarditis. [2010.10]
Assessment of the antimicrobial properties of maggots. [2010.06]
Treatment with monoclonal antibodies against Clostridium difficile toxins. [2010.01.21]
Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. [2010.01.15]
Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. [2010.01]
Multiple-dose safety, tolerability, and pharmacokinetics of oral nemonoxacin (TG-873870) in healthy volunteers. [2010.01]
Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers. [2010.01]
Treatment with monoclonal antibodies against Clostridium difficile toxins. [2010]
Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile
infection. [2010]
Safety and efficacy of intravenous tigecycline in subjects with secondary
bacteremia: pooled results from 8 phase III clinical trials. [2010]
Dose escalation study of the safety, tolerability, and pharmacokinetics of
nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone,
in healthy volunteers. [2010]
Prevention of Clostridium difficile infection with Saccharomyces boulardii: a systematic review. [2009.12]
Prevention of access-related infection in dialysis. [2009.12]
Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trial. [2009.12]
Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection. [2009.12]
Clinical characteristics and outcomes of diabetic patients with Staphylococcus aureus bacteremia and endocarditis. [2009.12]
Impact of an antimicrobial utilization program on antimicrobial use at a large teaching hospital: a randomized controlled trial. [2009.10]
[Current status of the management of pediatric infective endocarditis: a national survey] [2009.08]
Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections. [2009.07]
Linezolid for patients with neutropenia: are bacteriostatic agents appropriate? [2009.05]
Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy. [2009.05]
Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. [2009.03.15]
Affect of linezolid in ventilator-associated pneumonia caused by MRSA. [2009.03]
Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. [2009.01.15]
OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. [2009.01]
Clinical experience with daptomycin: bacteraemia and endocarditis. [2008.11]
Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections - a European perspective. [2008.10]
Linezolid for the treatment of infections caused by Gram-positive pathogens in China. [2008.09]
Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? [2008.08]
Comparison of tissue plasminogen activator-antibiotic locks with heparin-antibiotic locks in children with catheter-related bacteraemia. [2008.08]
Limited efficacy of a nonrestricted intervention on antimicrobial prescription of commonly used antibiotics in the hospital setting: results of a randomized controlled trial. [2008.07]
A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial. [2008.03.13]
Comparison of clinical and economic outcomes of two antibiotic prophylaxis regimens for sternal wound infection in high-risk patients following coronary artery bypass grafting surgery: a prospective randomised double-blind controlled trial. [2007.09]
Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. [2007.07.18]
Empiric Antimicrobial Therapy in Critical Illness: Results of a Surgical Infection Society Survey. [2007.06]
Incidence, microbiological findings, and clinical presentation of sternal wound infections after cardiac surgery with and without local gentamicin prophylaxis. [2007.02]
Serum Bactericidal Activities of High-Dose Daptomycin with and without Coadministration of Gentamicin against Isolates of Staphylococcus aureus and Enterococcus species. [2006.11]
Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. [2006.10]
Impact of ibuprofen administration on renal drug clearance in the first weeks of life. [2006.10]
|
